Close
Achema middle east
swop processing & packaging

Mitsubishi Tanabe Pharma Launch of VAFSEO,for the treatment of renal anemia in Japan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Syntegon delivers strong growth and EBITDA improvements in first half of 2025

Successful growth strategy delivers sales growth in H1...

Mitsubishi Tanabe Pharma Corporation announced that MTPC is launchingVAFSEO®Tablets 150mg and 300mg (VAFSEO®, vadadustat) which is anoralhypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in-licensed from Akebia Therapeutics, Inc., forthe treatment ofrenal anemiaon August 26, 2020,in Japan following today’s inclusion ofVAFSEO®in the NHI drug price listing.

Renal anemia can present prior to dialysis and at any time during hemodialysisor peritoneal dialysis. Symptoms associated with anemia include fatigue, shortness of breath, insomnia, headache, and decreased energy, which may decrease a patient’s quality of life (QOL). It is reported that renal anemia develops from an early stage of chronic kidney disease (CKD)and its frequency increases as CKD progresses*.VAFSEO®would provide patients with a once-daily treatment option in Japan and has the potential to set a new oral standard of care for the treatment of renal anemiain both dialysis and non-dialysis patients in Japan.

MTPCand Fuso Pharmaceutical Industries Ltd. which has strength in the dialysis fieldconcluded a co-marketing agreement concerning VAFSEO®in Japan, in May2020. Through this collaboration, the two companies will be able toprovide appropriate information to more healthcare professionalsin Japan.MTPCwill provide a new and convenient, oral therapeutic medication for renal anemia patients in Japan by promoting the appropriate usage of VAFSEO®.*KohaguraK, et al. Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese. Clin Exp Nephrol.2009

About VAFSEO
VAFSEO in-licensed from Akebia Therapeutics, Inc., is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor currently in global Phase 3 development for the treatment of anemia due to CKD. VAFSEO®is designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues.VAFSEO®was obtained manufacturing and marketing approvalbythe Ministry of Health, Labour and Welfare in Japan on June 29, 2020

Latest stories

Related stories

Sapio Sciences and Ultima Genomics Partner to Advance Multi-Omics Research

Partnership delivers global, end-to-end solutions to accelerate genomics research Sapio...

Symeres acquiries DGr Pharma to enhance regulatory expertise and broaden its biopharma capabilities

Symeres, a leading global Contract Research, Development and Manufacturing...

Syntegon delivers strong growth and EBITDA improvements in first half of 2025

Successful growth strategy delivers sales growth in H1...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »